Pharmaceutical company makes commitments to EU antitrust chief

A South African firm commits to reduce prices significantly on three crucial European cancer drugs to avoid abuse of its dominant market position. EU's competition commissioner is satisfied with costs saved for European healthcare system gleaned from the firm's pledge.


A 73-percent price reduction on six products, which will be valid for the next ten years. That's South African pharmaceutical firm Aspen's price for evading a potential fine from the EU Commission for breaching the EU's competition rules, according to a decision presented on Wednesday by European Commission Executive Vice President Margrethe Vestager.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs